# A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

> **NCT07705555** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 960 (estimated)

## Conditions studied

- Diabetic Retinopathy
- Macular Edema

## Interventions

- **DRUG:** MK-8748
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT07705555
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-27
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705555, "A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*